Search Results - "Burroni, Barbara"

Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study.

Authors: Belhadj, Maya Burroni, Barbara Kosmider, Olivier et al.

Source: British Journal of Haematology. Sep2023, Vol. 202 Issue 6, pe50-e53. 4p.

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Authors: Bonnet, Sarah Carillo, Serge Legrand, Baptiste et al.

Source: European Journal of Haematology. Mar2024, Vol. 112 Issue 3, p475-478. 4p.

Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma.

Authors: Kanaan, Christina Burroni, Barbara

Source: Blood. 10/18/2018, Vol. 132 Issue 16, p1725-1725. 1p.

Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T³ phase IB trial of the LYSA.

Authors: Tessoulin, Benoît Bouabdallah, Kamal Burroni, Barbara et al.

Source: Annals of Hematology. Aug2020, Vol. 99 Issue 8, p1771-1778. 8p.

Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.

Authors: Saleh, Khalil Cheminant, Morgane Chiron, David et al.

Source: Cancers. Jul2022, Vol. 14 Issue 13, pN.PAG-N.PAG. 21p.

Listeria-Associated Lymphadenitis: A Series of 11 Consecutive Cases and Review of the Literature.

Authors: Blot, Mathieu Disson, Olivier Leclercq, Alexandre et al.

Source: Open Forum Infectious Diseases. Jan2022, Vol. 9 Issue 1, p1-6. 6p.

Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis.

Authors: Vigneron, Clara Le Stang, Valentine Decroocq, Justine et al.

Source: Acta Oncologica. May2022, Vol. 61 Issue 5, p608-610. 3p. 1 Chart, 1 Graph.

EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Spleen: Report of an Aggressive Form With Molecular Characterization.

Authors: Baber, Alistair Legendre, Paul Palmic, Patricia et al.

Source: International Journal of Surgical Pathology. Feb2024, Vol. 32 Issue 1, p150-154. 5p.

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

Authors: Grignano, Eric Laurent, Jérémy Deau, Bénédicte et al.

Source: European Journal of Haematology. Aug2018, Vol. 101 Issue 2, p150-159. 10p.

Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients.

Authors: Parreau, Simon Nocturne, Gaétane Mariette, Xavier et al.

Source: Rheumatology. Sep2022, Vol. 61 Issue 9, p3818-3823. 6p.

Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer.

Authors: Alifano, Marco Mansuet-Lupo, Audrey Lococo, Filippo et al.

Source: PLoS ONE. Sep2014, Vol. 9 Issue 9, p1-11. 11p.

Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis.

Authors: Luque Paz, Damien Cottin, Laurane Lippert, Eric et al.

Source: Annals of Hematology. Apr2022, Vol. 101 Issue 4, p893-896. 4p.

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Authors: Renaud, Loïc Donzel, Marie Decroocq, Justine et al.

Source: European Journal of Cancer. May2025, Vol. 220, pN.PAG-N.PAG. 1p.

Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.

Authors: Cottin, Laurane Riou, Jérémie Orvain, Corentin et al.

Source: British Journal of Haematology. Mar2020, Vol. 188 Issue 6, p935-944. 10p. 2 Charts, 4 Graphs.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Authors: Raimbault, Anna Machherndl‐Spandl, Sigrid Itzykson, Raphaël et al.

Source: British Journal of Haematology. Feb2019, Vol. 184 Issue 4, p625-633. 9p. 4 Charts, 5 Graphs.

The tumor immune microenvironment of SCLC is not associated with its molecular subtypes.

Authors: Velut, Yoan Arqué, Basilia Wislez, Marie et al.

Source: European Journal of Cancer. Nov2024, Vol. 212, pN.PAG-N.PAG. 1p.

Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review.

Authors: Boudou-Rouquette, Pascaline Grignano, Eric Arrondeau, Jennifer et al.

Source: European Journal of Cancer. May2020, Vol. 130, p20-22. 3p.

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Authors: Damotte, Diane Warren, Sarah Arrondeau, Jennifer et al.

Source: Journal of Translational Medicine. 11/4/2019, Vol. 17 Issue 1, pN.PAG-N.PAG. 1p.

Immune-related bone marrow failure following anti-PD1 therapy.

Authors: Michot, Jean-Marie Vargaftig, Jacques Leduc, Charlotte et al.

Source: European Journal of Cancer. Jul2017, Vol. 80, p1-4. 4p.

Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge.

Authors: Kime, Amel Bréal, Claire Cottereau, Anne-Ségolène et al.

Source: Blood Cells, Molecules & Diseases. Dec2021, Vol. 92, pN.PAG-N.PAG. 1p.